A randomized placebo-controlled PET study of ketamine´s effect on serotonin1B receptor binding in patients with SSRI-resistant depression

The glutamate N -methyl- d -aspartate receptor antagonist ketamine has a rapid antidepressant effect. Despite large research efforts, ketamine’s mechanism of action in major depressive disorder (MDD) has still not been determined. In rodents, the antidepressant properties of ketamine were found to b...

Full description

Saved in:
Bibliographic Details
Published inTranslational psychiatry Vol. 10; no. 1; p. 159
Main Authors Tiger, Mikael, Veldman, Emma R., Ekman, Carl-Johan, Halldin, Christer, Svenningsson, Per, Lundberg, Johan
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.06.2020
Nature Publishing Group
Subjects
59/78
631/154/436/2388
692/53/2423
692/699/476/1414
Antidepressants
Behavioral Sciences
Biological Psychology
Ketamine
Medicine
Medicine & Public Health
Neurosciences
Pharmacotherapy
Psychiatry
Online AccessGet full text

Cover

Abstract The glutamate N -methyl- d -aspartate receptor antagonist ketamine has a rapid antidepressant effect. Despite large research efforts, ketamine’s mechanism of action in major depressive disorder (MDD) has still not been determined. In rodents, the antidepressant properties of ketamine were found to be dependent on both the α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and the serotonin (5-HT) 1B receptor. Low 5-HT 1B receptor binding in limbic brain regions is a replicated finding in MDD. In non-human primates, AMPA-dependent increase in 5-HT 1B receptor binding in the ventral striatum (VST) has been demonstrated after ketamine infusion. Thirty selective serotonin reuptake inhibitor-resistant MDD patients were recruited via advertisement and randomized to double-blind monotherapy with 0.5 mg/kg ketamine or placebo infusion. The patients were examined with the 5-HT 1B receptor selective radioligand [ 11 C]AZ10419369 and positron emission tomography (PET) before and 24–72 h after treatment. 5-HT 1B receptor binding did not significantly alter in patients treated with ketamine compared with placebo. An increase in 5-HT 1B receptor binding with 16.7 % ( p  = 0.036) was found in the hippocampus after one ketamine treatment. 5-HT 1B receptor binding in VST at baseline correlated with MDD symptom ratings ( r  = −0.426, p  = 0.019) and with reduction of depressive symptoms with ketamine ( r  = −0.644, p  = 0.002). In conclusion, reduction of depressive symptoms in MDD patients after ketamine treatment is correlated inversely with baseline 5-HT 1B receptor binding in VST. Further studies examining the role of 5-HT 1B receptors in the antidepressant mechanism of action of ketamine should be conducted, homing in on the 5-HT 1B receptor as an MDD treatment response marker.
AbstractList The glutamate N-methyl-D-aspartate receptor antagonist ketamine has a rapid antidepressant effect. Despite large research efforts, ketamine's mechanism of action in major depressive disorder (MDD) has still not been determined. In rodents, the antidepressant properties of ketamine were found to be dependent on both the α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and the serotonin (5-HT)1B receptor. Low 5-HT1B receptor binding in limbic brain regions is a replicated finding in MDD. In non-human primates, AMPA-dependent increase in 5-HT1B receptor binding in the ventral striatum (VST) has been demonstrated after ketamine infusion. Thirty selective serotonin reuptake inhibitor-resistant MDD patients were recruited via advertisement and randomized to double-blind monotherapy with 0.5 mg/kg ketamine or placebo infusion. The patients were examined with the 5-HT1B receptor selective radioligand [11C]AZ10419369 and positron emission tomography (PET) before and 24-72 h after treatment. 5-HT1B receptor binding did not significantly alter in patients treated with ketamine compared with placebo. An increase in 5-HT1B receptor binding with 16.7 % (p = 0.036) was found in the hippocampus after one ketamine treatment. 5-HT1B receptor binding in VST at baseline correlated with MDD symptom ratings (r = -0.426, p = 0.019) and with reduction of depressive symptoms with ketamine (r = -0.644, p = 0.002). In conclusion, reduction of depressive symptoms in MDD patients after ketamine treatment is correlated inversely with baseline 5-HT1B receptor binding in VST. Further studies examining the role of 5-HT1B receptors in the antidepressant mechanism of action of ketamine should be conducted, homing in on the 5-HT1B receptor as an MDD treatment response marker.The glutamate N-methyl-D-aspartate receptor antagonist ketamine has a rapid antidepressant effect. Despite large research efforts, ketamine's mechanism of action in major depressive disorder (MDD) has still not been determined. In rodents, the antidepressant properties of ketamine were found to be dependent on both the α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and the serotonin (5-HT)1B receptor. Low 5-HT1B receptor binding in limbic brain regions is a replicated finding in MDD. In non-human primates, AMPA-dependent increase in 5-HT1B receptor binding in the ventral striatum (VST) has been demonstrated after ketamine infusion. Thirty selective serotonin reuptake inhibitor-resistant MDD patients were recruited via advertisement and randomized to double-blind monotherapy with 0.5 mg/kg ketamine or placebo infusion. The patients were examined with the 5-HT1B receptor selective radioligand [11C]AZ10419369 and positron emission tomography (PET) before and 24-72 h after treatment. 5-HT1B receptor binding did not significantly alter in patients treated with ketamine compared with placebo. An increase in 5-HT1B receptor binding with 16.7 % (p = 0.036) was found in the hippocampus after one ketamine treatment. 5-HT1B receptor binding in VST at baseline correlated with MDD symptom ratings (r = -0.426, p = 0.019) and with reduction of depressive symptoms with ketamine (r = -0.644, p = 0.002). In conclusion, reduction of depressive symptoms in MDD patients after ketamine treatment is correlated inversely with baseline 5-HT1B receptor binding in VST. Further studies examining the role of 5-HT1B receptors in the antidepressant mechanism of action of ketamine should be conducted, homing in on the 5-HT1B receptor as an MDD treatment response marker.
The glutamate N -methyl- d -aspartate receptor antagonist ketamine has a rapid antidepressant effect. Despite large research efforts, ketamine’s mechanism of action in major depressive disorder (MDD) has still not been determined. In rodents, the antidepressant properties of ketamine were found to be dependent on both the α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and the serotonin (5-HT) 1B receptor. Low 5-HT 1B receptor binding in limbic brain regions is a replicated finding in MDD. In non-human primates, AMPA-dependent increase in 5-HT 1B receptor binding in the ventral striatum (VST) has been demonstrated after ketamine infusion. Thirty selective serotonin reuptake inhibitor-resistant MDD patients were recruited via advertisement and randomized to double-blind monotherapy with 0.5 mg/kg ketamine or placebo infusion. The patients were examined with the 5-HT 1B receptor selective radioligand [ 11 C]AZ10419369 and positron emission tomography (PET) before and 24–72 h after treatment. 5-HT 1B receptor binding did not significantly alter in patients treated with ketamine compared with placebo. An increase in 5-HT 1B receptor binding with 16.7 % ( p  = 0.036) was found in the hippocampus after one ketamine treatment. 5-HT 1B receptor binding in VST at baseline correlated with MDD symptom ratings ( r  = −0.426, p  = 0.019) and with reduction of depressive symptoms with ketamine ( r  = −0.644, p  = 0.002). In conclusion, reduction of depressive symptoms in MDD patients after ketamine treatment is correlated inversely with baseline 5-HT 1B receptor binding in VST. Further studies examining the role of 5-HT 1B receptors in the antidepressant mechanism of action of ketamine should be conducted, homing in on the 5-HT 1B receptor as an MDD treatment response marker.
The glutamate N-methyl-d-aspartate receptor antagonist ketamine has a rapid antidepressant effect. Despite large research efforts, ketamine’s mechanism of action in major depressive disorder (MDD) has still not been determined. In rodents, the antidepressant properties of ketamine were found to be dependent on both the α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and the serotonin (5-HT)1B receptor. Low 5-HT1B receptor binding in limbic brain regions is a replicated finding in MDD. In non-human primates, AMPA-dependent increase in 5-HT1B receptor binding in the ventral striatum (VST) has been demonstrated after ketamine infusion. Thirty selective serotonin reuptake inhibitor-resistant MDD patients were recruited via advertisement and randomized to double-blind monotherapy with 0.5 mg/kg ketamine or placebo infusion. The patients were examined with the 5-HT1B receptor selective radioligand [11C]AZ10419369 and positron emission tomography (PET) before and 24–72 h after treatment. 5-HT1B receptor binding did not significantly alter in patients treated with ketamine compared with placebo. An increase in 5-HT1B receptor binding with 16.7 % (p = 0.036) was found in the hippocampus after one ketamine treatment. 5-HT1B receptor binding in VST at baseline correlated with MDD symptom ratings (r = −0.426, p = 0.019) and with reduction of depressive symptoms with ketamine (r = −0.644, p = 0.002). In conclusion, reduction of depressive symptoms in MDD patients after ketamine treatment is correlated inversely with baseline 5-HT1B receptor binding in VST. Further studies examining the role of 5-HT1B receptors in the antidepressant mechanism of action of ketamine should be conducted, homing in on the 5-HT1B receptor as an MDD treatment response marker.
ArticleNumber 159
Author Halldin, Christer
Ekman, Carl-Johan
Svenningsson, Per
Lundberg, Johan
Tiger, Mikael
Veldman, Emma R.
Author_xml – sequence: 1
  givenname: Mikael
  orcidid: 0000-0001-8495-8125
  surname: Tiger
  fullname: Tiger, Mikael
  email: mikael.tiger@ki.se
  organization: Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services
– sequence: 2
  givenname: Emma R.
  orcidid: 0000-0003-0393-8400
  surname: Veldman
  fullname: Veldman, Emma R.
  organization: Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services
– sequence: 3
  givenname: Carl-Johan
  surname: Ekman
  fullname: Ekman, Carl-Johan
  organization: Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services
– sequence: 4
  givenname: Christer
  surname: Halldin
  fullname: Halldin, Christer
  organization: Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services
– sequence: 5
  givenname: Per
  surname: Svenningsson
  fullname: Svenningsson, Per
  organization: Department of Clinical Neuroscience, Karolinska Institutet
– sequence: 6
  givenname: Johan
  surname: Lundberg
  fullname: Lundberg, Johan
  organization: Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services
BookMark eNp9kk1uFDEQhS0URELIAdhZYsOmg_96umaDFKIQIkUCkbC23Hb1xKHHbmx3UDgC5-EEnAyPJgiIRLyxy_5eqcr1npKdEAMS8pyzQ84kvMqKyyU0TLCGgVKNekT2BG-hkRxg56_zLjnI-ZrV1SrgHX9CdqVQXbuE5R75fkSTCS6u_Td0dBqNxT42NoaS4jjWqw8nlzSX2d3SONDPWMzaB_z5I1McBrSFxkAzplhi8IG_oQktTiUm2vvgfFhRH-hkisdQMv3qyxW9uPh41iTMPhcTCnU41SD7GJ6Rx4MZMx7c7fvk09uTy-N3zfn707Pjo_PG1qJLs2DYutbYVhrBGWLvpGoZMNM5iU72zoHrjRSGcbcQtgMxKClZx6zsesFA7pPX27zT3K_R2VpaMqOekl-bdKuj8frfl-Cv9Cre6E4sODBeE7y8S5Dilxlz0WufLY6jCRjnrIVi0EoAWFT0xT30Os4p1PYqBZ1oK8QfphjUOTNYVqrbUjbFnBMO2vpSv3YzK-NHzZneGENvjaGrMfTGGFpVJb-n_N3sQxqx1eTKhhWmPzX9X_QLF9rNjw
CitedBy_id crossref_primary_10_1016_j_jpsychires_2022_10_062
crossref_primary_10_1016_j_biopha_2022_113030
crossref_primary_10_1016_j_jad_2024_10_042
crossref_primary_10_1016_j_pbb_2024_173917
crossref_primary_10_1016_j_jad_2021_07_060
crossref_primary_10_1016_j_jad_2023_10_120
crossref_primary_10_1016_j_jad_2024_04_039
crossref_primary_10_1016_j_jad_2021_04_055
crossref_primary_10_1002_pcn5_70042
crossref_primary_10_1016_j_eclinm_2023_102127
crossref_primary_10_3390_biom13091411
crossref_primary_10_1038_s41398_022_02290_5
crossref_primary_10_1111_cns_14464
crossref_primary_10_3389_fnins_2021_698633
crossref_primary_10_1038_s41386_022_01369_3
crossref_primary_10_31857_S1027813323030081
crossref_primary_10_1002_14651858_CD011612_pub3
crossref_primary_10_3389_fpsyt_2022_864902
crossref_primary_10_3390_brainsci12101329
crossref_primary_10_1038_s41380_022_01757_7
crossref_primary_10_1134_S181971242303008X
crossref_primary_10_2217_pmt_2023_0066
crossref_primary_10_1111_jnc_15615
crossref_primary_10_1038_s41386_023_01632_1
crossref_primary_10_4103_bjoa_bjoa_81_23
crossref_primary_10_1016_S2215_0366_23_00183_9
crossref_primary_10_1177_17470218221144614
crossref_primary_10_3389_fpsyt_2024_1372650
crossref_primary_10_1007_s11064_023_04061_0
crossref_primary_10_1093_ijnp_pyae021
crossref_primary_10_1038_s41398_022_01989_9
crossref_primary_10_1146_annurev_med_051322_120608
crossref_primary_10_1016_j_jns_2022_120152
crossref_primary_10_1016_j_bja_2023_06_044
crossref_primary_10_1016_j_neuropharm_2023_109422
crossref_primary_10_1016_j_bpsc_2022_11_005
crossref_primary_10_3389_fpsyt_2023_1128406
crossref_primary_10_1016_j_bcp_2021_114892
crossref_primary_10_1097_PRA_0000000000000787
crossref_primary_10_3389_fpsyt_2024_1322118
crossref_primary_10_1177_0271678X211049185
crossref_primary_10_1038_s41380_024_02853_6
crossref_primary_10_3390_membranes13090800
Cites_doi 10.1176/appi.ajp.2011.11010137
10.1097/00004728-198102000-00027
10.1007/s11920-007-0063-1
10.1021/acschemneuro.7b00074
10.1016/j.neuroscience.2015.04.047
10.1038/sj.npp.1301131
10.1016/j.neuron.2019.03.013
10.1176/jnp.9.3.471
10.1038/jcbfm.2011.172
10.1007/s00213-010-1881-0
10.1007/s00213-018-4872-1
10.1006/nimg.1996.0066
10.1046/j.1525-1497.2001.016009606.x
10.1038/s41586-020-2158-3
10.1111/pcn.12980
10.1016/j.biopsych.2007.05.028
10.1007/s00259-013-2529-1
10.1038/jcbfm.2010.55
10.1192/bjp.134.4.382
10.1016/j.pscychresns.2016.04.016
10.1093/comjnl/7.4.308
10.1007/s40263-013-0097-3
10.1016/S0006-3223(99)00230-9
10.1016/j.pnpbp.2016.05.007
10.1001/archgenpsychiatry.2011.91
10.1002/syn.21761
10.1038/tp.2013.112
10.1021/acschemneuro.9b00288
10.3389/fphar.2017.00978
10.1016/0168-8510(90)90421-9
10.1016/j.pharmthera.2006.08.004
10.1016/S0006-3223(02)01866-8
10.1017/S1461145712001617
10.1016/S0165-0327(00)00242-1
10.1016/j.neuroimage.2017.04.031
10.1016/S0006-8993(01)02823-2
10.1016/j.neuroimage.2011.09.015
10.1016/j.pbb.2017.12.010
10.1038/mp.2017.190
10.1038/mp.2015.176
10.1176/appi.ajp.2018.18020138
10.1007/s00259-009-1156-3
10.1016/j.brainresrev.2008.07.006
10.1017/S1461145711001945
10.1093/ijnp/pyz041
ContentType Journal Article
Copyright The Author(s) 2020
The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2020
– notice: The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1038/s41398-020-0844-4
DatabaseName Springer Nature OA Free Journals
CrossRef
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

Publicly Available Content Database
CrossRef

Publicly Available Content Database
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2158-3188
ExternalDocumentID PMC7261801
10_1038_s41398_020_0844_4
GrantInformation_xml – fundername: Vetenskapsrådet (Swedish Research Council)
  grantid: 2013-09304; 2013-09304
  funderid: https://doi.org/10.13039/501100004359
– fundername: ;
  grantid: 2013-09304; 2013-09304
GroupedDBID ---
0R~
3V.
53G
5VS
7X7
88E
8FI
8FJ
AAJSJ
AAKDD
ABUWG
ACGFO
ACGFS
ACMJI
ACSMW
ADBBV
ADFRT
AENEX
AFKRA
AHMBA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMTXH
AOIJS
BAWUL
BCNDV
BENPR
BPHCQ
BVXVI
C6C
CCPQU
DIK
EBLON
EBS
EMOBN
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
KQ8
LGEZI
LOTEE
M1P
M~E
NADUK
NAO
NXXTH
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNS
RNT
RNTTT
RPM
SNYQT
UKHRP
AASML
AAYXX
CITATION
PHGZM
PHGZT
7XB
8FK
AARCD
AZQEC
DWQXO
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c475t-60e5d5ac53a210eebd345080a7d3ed3bdd8dba32a01d62c782f433070c37b2083
IEDL.DBID AAJSJ
ISSN 2158-3188
IngestDate Thu Aug 21 13:52:47 EDT 2025
Mon Jul 21 10:18:13 EDT 2025
Fri Aug 08 08:40:59 EDT 2025
Wed Aug 13 07:17:44 EDT 2025
Thu Apr 24 23:09:24 EDT 2025
Tue Jul 01 00:55:11 EDT 2025
Fri Feb 21 02:39:01 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c475t-60e5d5ac53a210eebd345080a7d3ed3bdd8dba32a01d62c782f433070c37b2083
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ORCID 0000-0003-0393-8400
0000-0001-8495-8125
OpenAccessLink https://www.nature.com/articles/s41398-020-0844-4
PMID 32475989
PQID 2408139089
PQPubID 2041978
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_7261801
proquest_miscellaneous_2408538886
proquest_journals_2487258861
proquest_journals_2408139089
crossref_citationtrail_10_1038_s41398_020_0844_4
crossref_primary_10_1038_s41398_020_0844_4
springer_journals_10_1038_s41398_020_0844_4
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-06-01
PublicationDateYYYYMMDD 2020-06-01
PublicationDate_xml – month: 06
  year: 2020
  text: 2020-06-01
  day: 01
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle Translational psychiatry
PublicationTitleAbbrev Transl Psychiatry
PublicationYear 2020
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References Knowland, Lim (CR18) 2018; 174
Shulman, Herrmann, Walker (CR7) 2013; 27
Tiger (CR45) 2014; 68
Mead (CR39) 1965; 7
Varnas (CR24) 2011; 31
Rush (CR32) 2006; 31
Mayberg (CR41) 1997; 9
Murrough (CR15) 2011; 213
Bergstrom (CR33) 1981; 5
Yamanaka (CR17) 2014; 4
Murrough (CR14) 2011; 68
EuroQol (CR29) 1990; 16
CR35
du Jardin (CR8) 2016; 71
Varrone (CR34) 2009; 36
Montgomery, Asberg (CR30) 1979; 134
Maeng (CR4) 2008; 63
Nord, Finnema, Halldin, Farde (CR16) 2013; 16
Williams (CR23) 2018; 175
Malykhin, Coupland (CR40) 2015; 309
Tiger (CR47) 2020; 74
Lundberg, Tiger, Landen, Halldin, Farde (CR6) 2012; 15
du Jardin (CR11) 2017; 8
Tiger, Varnas, Okubo, Lundberg (CR12) 2018; 235
Tyler, Yourish, Ionescu, Haggarty (CR5) 2017; 8
Guy (CR28) 1976
Varnas, Hall, Bonaventure, Sedvall (CR19) 2001; 915
Carreno (CR43) 2016; 21
Alex, Pehek (CR20) 2007; 113
Li, Jasanoff (CR21) 2020; 580
Robinson, Cools, Carlisi, Sahakian, Drevets (CR46) 2012; 169
CR9
Kokkinou, Ashok, Howes (CR22) 2018; 23
Jenkinson, Beckmann, Behrens, Woolrich, Smith (CR36) 2012; 62
Berman (CR1) 2000; 47
Nord, Finnema, Schain, Halldin, Farde (CR48) 2014; 41
Svanborg, Asberg (CR25) 2001; 64
Tiger (CR13) 2016; 253
Rush (CR31) 2003; 54
Sheehan (CR27) 1998; 59
Lopez-Gil (CR10) 2019; 10
Kroenke, Spitzer, Williams (CR26) 2001; 16
Finnema, Varrone, Hwang, Halldin, Farde (CR44) 2012; 32
Matheson (CR38) 2017; 155
Maeng, Zarate (CR2) 2007; 9
Gunduz-Bruce (CR3) 2009; 60
Lammertsma, Hume (CR37) 1996; 4
Duman, Sanacora, Krystal (CR42) 2019; 102
MW Tyler (844_CR5) 2017; 8
KG du Jardin (844_CR8) 2016; 71
M Bergstrom (844_CR33) 1981; 5
844_CR9
AA Lammertsma (844_CR37) 1996; 4
M Tiger (844_CR45) 2014; 68
OJ Robinson (844_CR46) 2012; 169
K Kroenke (844_CR26) 2001; 16
M Nord (844_CR48) 2014; 41
NR Williams (844_CR23) 2018; 175
M Tiger (844_CR13) 2016; 253
NA Mead (844_CR39) 1965; 7
RM Berman (844_CR1) 2000; 47
HS Mayberg (844_CR41) 1997; 9
SJ Finnema (844_CR44) 2012; 32
KI Shulman (844_CR7) 2013; 27
RS Duman (844_CR42) 2019; 102
P Svanborg (844_CR25) 2001; 64
SA Montgomery (844_CR30) 1979; 134
D Knowland (844_CR18) 2018; 174
KD Alex (844_CR20) 2007; 113
K Varnas (844_CR24) 2011; 31
M Tiger (844_CR47) 2020; 74
DV Sheehan (844_CR27) 1998; 59
N Li (844_CR21) 2020; 580
AJ Rush (844_CR31) 2003; 54
H Yamanaka (844_CR17) 2014; 4
K Varnas (844_CR19) 2001; 915
JW Murrough (844_CR14) 2011; 68
FR Carreno (844_CR43) 2016; 21
AJ Rush (844_CR32) 2006; 31
S Maeng (844_CR2) 2007; 9
844_CR35
KG du Jardin (844_CR11) 2017; 8
GJ Matheson (844_CR38) 2017; 155
M Kokkinou (844_CR22) 2018; 23
NV Malykhin (844_CR40) 2015; 309
M Nord (844_CR16) 2013; 16
S Maeng (844_CR4) 2008; 63
M Tiger (844_CR12) 2018; 235
M Jenkinson (844_CR36) 2012; 62
A Varrone (844_CR34) 2009; 36
G EuroQol (844_CR29) 1990; 16
X Lopez-Gil (844_CR10) 2019; 10
H Gunduz-Bruce (844_CR3) 2009; 60
W Guy (844_CR28) 1976
J Lundberg (844_CR6) 2012; 15
JW Murrough (844_CR15) 2011; 213
References_xml – volume: 169
  start-page: 152
  year: 2012
  end-page: 159
  ident: CR46
  article-title: Ventral striatum response during reward and punishment reversal learning in unmedicated major depressive disorder
  publication-title: Am. J. Psychiatry
  doi: 10.1176/appi.ajp.2011.11010137
– volume: 5
  start-page: 136
  year: 1981
  end-page: 141
  ident: CR33
  article-title: Head fixation device for reproducible position alignment in transmission CT and positron emission tomography
  publication-title: J. Comput. Assist. Tomogr.
  doi: 10.1097/00004728-198102000-00027
– volume: 9
  start-page: 467
  year: 2007
  end-page: 474
  ident: CR2
  article-title: The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects
  publication-title: Curr. Psychiatry Rep.
  doi: 10.1007/s11920-007-0063-1
– volume: 8
  start-page: 1122
  year: 2017
  end-page: 1134
  ident: CR5
  article-title: Classics in chemical neuroscience: ketamine
  publication-title: ACS Chem. Neurosci.
  doi: 10.1021/acschemneuro.7b00074
– volume: 309
  start-page: 200
  year: 2015
  end-page: 213
  ident: CR40
  article-title: Hippocampal neuroplasticity in major depressive disorder
  publication-title: Neuroscience
  doi: 10.1016/j.neuroscience.2015.04.047
– volume: 31
  start-page: 1841
  year: 2006
  end-page: 1853
  ident: CR32
  article-title: Report by the ACNP Task Force on response and remission in major depressive disorder
  publication-title: Neuropsychopharmacology
  doi: 10.1038/sj.npp.1301131
– volume: 102
  start-page: 75
  year: 2019
  end-page: 90
  ident: CR42
  article-title: Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments
  publication-title: Neuron
  doi: 10.1016/j.neuron.2019.03.013
– volume: 9
  start-page: 471
  year: 1997
  end-page: 481
  ident: CR41
  article-title: Limbic-cortical dysregulation: a proposed model of depression
  publication-title: J. Neuropsychiatry Clin. Neurosci.
  doi: 10.1176/jnp.9.3.471
– volume: 32
  start-page: 685
  year: 2012
  end-page: 695
  ident: CR44
  article-title: Confirmation of fenfluramine effect on 5-HT(1B) receptor binding of [(11)C]AZ10419369 using an equilibrium approach
  publication-title: J. Cereb. Blood Flow. Metab.
  doi: 10.1038/jcbfm.2011.172
– volume: 59
  start-page: 22
  issue: Suppl 20
  year: 1998
  end-page: 33
  ident: CR27
  article-title: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10
  publication-title: J. Clin. Psychiatry
– volume: 213
  start-page: 547
  year: 2011
  end-page: 553
  ident: CR15
  article-title: Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder
  publication-title: Psychopharmacology (Berl.)
  doi: 10.1007/s00213-010-1881-0
– volume: 235
  start-page: 1317
  year: 2018
  end-page: 1334
  ident: CR12
  article-title: The 5-HT1B receptor - a potential target for antidepressant treatment
  publication-title: Psychopharmacology (Berl.)
  doi: 10.1007/s00213-018-4872-1
– ident: CR35
– volume: 4
  start-page: 153
  year: 1996
  end-page: 158
  ident: CR37
  article-title: Simplified reference tissue model for PET receptor studies
  publication-title: Neuroimage
  doi: 10.1006/nimg.1996.0066
– volume: 16
  start-page: 606
  year: 2001
  end-page: 613
  ident: CR26
  article-title: The PHQ-9: validity of a brief depression severity measure
  publication-title: J. Gen. Intern. Med.
  doi: 10.1046/j.1525-1497.2001.016009606.x
– volume: 580
  start-page: 239
  year: 2020
  end-page: 244
  ident: CR21
  article-title: Local and global consequences of reward-evoked striatal dopamine release
  publication-title: Nature
  doi: 10.1038/s41586-020-2158-3
– volume: 74
  start-page: 263
  year: 2020
  end-page: 269
  ident: CR47
  article-title: [(11) C]raclopride positron emission tomography study of dopamine-D2/3 receptor binding in patients with severe major depressive episodes before and after electroconvulsive therapy and compared to control subjects
  publication-title: Psychiatry Clin. Neurosci.
  doi: 10.1111/pcn.12980
– volume: 63
  start-page: 349
  year: 2008
  end-page: 352
  ident: CR4
  article-title: Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors
  publication-title: Biol. Psychiatry
  doi: 10.1016/j.biopsych.2007.05.028
– volume: 41
  start-page: 301
  year: 2014
  end-page: 307
  ident: CR48
  article-title: Test-retest reliability of [(11)C]AZ10419369 binding to 5-HT 1B receptors in human brain
  publication-title: Eur. J. Nucl. Med. Mol. Imaging
  doi: 10.1007/s00259-013-2529-1
– volume: 31
  start-page: 113
  year: 2011
  end-page: 123
  ident: CR24
  article-title: Quantitative analysis of [11C]AZ10419369 binding to 5-HT1B receptors in human brain
  publication-title: J. Cereb. Blood Flow. Metab.
  doi: 10.1038/jcbfm.2010.55
– volume: 134
  start-page: 382
  year: 1979
  end-page: 389
  ident: CR30
  article-title: A new depression scale designed to be sensitive to change
  publication-title: Br. J. Psychiatry
  doi: 10.1192/bjp.134.4.382
– volume: 253
  start-page: 36
  year: 2016
  end-page: 42
  ident: CR13
  article-title: Low serotonin1B receptor binding potential in the anterior cingulate cortex in drug-free patients with recurrent major depressive disorder
  publication-title: Psychiatry Res.
  doi: 10.1016/j.pscychresns.2016.04.016
– volume: 7
  start-page: 308
  year: 1965
  end-page: 313
  ident: CR39
  article-title: A simplex method for function mimimization
  publication-title: Comput. J.
  doi: 10.1093/comjnl/7.4.308
– volume: 27
  start-page: 789
  year: 2013
  end-page: 797
  ident: CR7
  article-title: Current place of monoamine oxidase inhibitors in the treatment of depression
  publication-title: CNS Drugs
  doi: 10.1007/s40263-013-0097-3
– volume: 47
  start-page: 351
  year: 2000
  end-page: 354
  ident: CR1
  article-title: Antidepressant effects of ketamine in depressed patients
  publication-title: Biol. Psychiatry
  doi: 10.1016/S0006-3223(99)00230-9
– volume: 71
  start-page: 27
  year: 2016
  end-page: 38
  ident: CR8
  article-title: Potential involvement of serotonergic signaling in ketamine’s antidepressant actions: a critical review
  publication-title: Prog. Neuropsychopharmacol. Biol. Psychiatry
  doi: 10.1016/j.pnpbp.2016.05.007
– volume: 68
  start-page: 892
  year: 2011
  end-page: 900
  ident: CR14
  article-title: The effect of early trauma exposure on serotonin type 1B receptor expression revealed by reduced selective radioligand binding
  publication-title: Arch. Gen. Psychiatry
  doi: 10.1001/archgenpsychiatry.2011.91
– volume: 68
  start-page: 480
  year: 2014
  end-page: 483
  ident: CR45
  article-title: No correlation between serotonin and its metabolite 5-HIAA in the cerebrospinal fluid and [(11) C]AZ10419369 binding measured with PET in healthy volunteers
  publication-title: Synapse
  doi: 10.1002/syn.21761
– volume: 4
  year: 2014
  ident: CR17
  article-title: A possible mechanism of the nucleus accumbens and ventral pallidum 5-HT1B receptors underlying the antidepressant action of ketamine: a PET study with macaques
  publication-title: Transl. Psychiatry
  doi: 10.1038/tp.2013.112
– volume: 10
  start-page: 3318
  year: 2019
  end-page: 3326
  ident: CR10
  article-title: Role of serotonin and noradrenaline in the rapid antidepressant action of ketamine
  publication-title: ACS Chem. Neurosci.
  doi: 10.1021/acschemneuro.9b00288
– volume: 8
  start-page: 978
  year: 2017
  ident: CR11
  article-title: S-ketamine mediates its acute and sustained antidepressant-like activity through a 5-HT1B receptor dependent mechanism in a genetic rat model of depression
  publication-title: Front. Pharm.
  doi: 10.3389/fphar.2017.00978
– volume: 16
  start-page: 199
  year: 1990
  end-page: 208
  ident: CR29
  article-title: EuroQol-a new facility for the measurement of health-related quality of life
  publication-title: Health Policy
  doi: 10.1016/0168-8510(90)90421-9
– year: 1976
  ident: CR28
  publication-title: ECDEU Assessment Manual for Psychopharmacology
– volume: 113
  start-page: 296
  year: 2007
  end-page: 320
  ident: CR20
  article-title: Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission
  publication-title: Pharm. Ther.
  doi: 10.1016/j.pharmthera.2006.08.004
– volume: 54
  start-page: 573
  year: 2003
  end-page: 583
  ident: CR31
  article-title: The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression
  publication-title: Biol. Psychiatry
  doi: 10.1016/S0006-3223(02)01866-8
– ident: CR9
– volume: 16
  start-page: 1577
  year: 2013
  end-page: 1586
  ident: CR16
  article-title: Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain
  publication-title: Int. J. Neuropsychopharmacol.
  doi: 10.1017/S1461145712001617
– volume: 64
  start-page: 203
  year: 2001
  end-page: 216
  ident: CR25
  article-title: A comparison between the Beck Depression Inventory (BDI) and the self-rating version of the Montgomery Asberg Depression Rating Scale (MADRS)
  publication-title: J. Affect Disord.
  doi: 10.1016/S0165-0327(00)00242-1
– volume: 155
  start-page: 344
  year: 2017
  end-page: 353
  ident: CR38
  article-title: Reliability of volumetric and surface-based normalisation and smoothing techniques for PET analysis of the cortex: a test-retest analysis using [(11)C]SCH-23390
  publication-title: Neuroimage
  doi: 10.1016/j.neuroimage.2017.04.031
– volume: 915
  start-page: 47
  year: 2001
  end-page: 57
  ident: CR19
  article-title: Autoradiographic mapping of 5-HT(1B) and 5-HT(1D) receptors in the post mortem human brain using [(3)H]GR 125743
  publication-title: Brain Res.
  doi: 10.1016/S0006-8993(01)02823-2
– volume: 62
  start-page: 782
  year: 2012
  end-page: 790
  ident: CR36
  article-title: Fsl
  publication-title: Neuroimage
  doi: 10.1016/j.neuroimage.2011.09.015
– volume: 174
  start-page: 42
  year: 2018
  end-page: 52
  ident: CR18
  article-title: Circuit-based frameworks of depressive behaviors: The role of reward circuitry and beyond
  publication-title: Pharm. Biochem. Behav.
  doi: 10.1016/j.pbb.2017.12.010
– volume: 23
  start-page: 59
  year: 2018
  end-page: 69
  ident: CR22
  article-title: The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders
  publication-title: Mol. Psychiatry
  doi: 10.1038/mp.2017.190
– volume: 21
  start-page: 1298
  year: 2016
  end-page: 1308
  ident: CR43
  article-title: Activation of a ventral hippocampus-medial prefrontal cortex pathway is both necessary and sufficient for an antidepressant response to ketamine
  publication-title: Mol. Psychiatry
  doi: 10.1038/mp.2015.176
– volume: 175
  start-page: 1205
  year: 2018
  end-page: 1215
  ident: CR23
  article-title: Attenuation of antidepressant effects of ketamine by opioid receptor antagonism
  publication-title: Am. J. Psychiatry
  doi: 10.1176/appi.ajp.2018.18020138
– volume: 36
  start-page: 1639
  year: 2009
  end-page: 1650
  ident: CR34
  article-title: Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT
  publication-title: Eur. J. Nucl. Med. Mol. Imaging
  doi: 10.1007/s00259-009-1156-3
– volume: 60
  start-page: 279
  year: 2009
  end-page: 286
  ident: CR3
  article-title: The acute effects of NMDA antagonism: from the rodent to the human brain
  publication-title: Brain Res. Rev.
  doi: 10.1016/j.brainresrev.2008.07.006
– volume: 15
  start-page: 1167
  year: 2012
  end-page: 1172
  ident: CR6
  article-title: Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder
  publication-title: Int. J. Neuropsychopharmacol.
  doi: 10.1017/S1461145711001945
– volume: 74
  start-page: 263
  year: 2020
  ident: 844_CR47
  publication-title: Psychiatry Clin. Neurosci.
  doi: 10.1111/pcn.12980
– ident: 844_CR9
  doi: 10.1093/ijnp/pyz041
– volume: 16
  start-page: 1577
  year: 2013
  ident: 844_CR16
  publication-title: Int. J. Neuropsychopharmacol.
  doi: 10.1017/S1461145712001617
– volume: 4
  start-page: 153
  year: 1996
  ident: 844_CR37
  publication-title: Neuroimage
  doi: 10.1006/nimg.1996.0066
– volume: 155
  start-page: 344
  year: 2017
  ident: 844_CR38
  publication-title: Neuroimage
  doi: 10.1016/j.neuroimage.2017.04.031
– volume: 27
  start-page: 789
  year: 2013
  ident: 844_CR7
  publication-title: CNS Drugs
  doi: 10.1007/s40263-013-0097-3
– volume: 175
  start-page: 1205
  year: 2018
  ident: 844_CR23
  publication-title: Am. J. Psychiatry
  doi: 10.1176/appi.ajp.2018.18020138
– volume: 253
  start-page: 36
  year: 2016
  ident: 844_CR13
  publication-title: Psychiatry Res.
  doi: 10.1016/j.pscychresns.2016.04.016
– volume: 5
  start-page: 136
  year: 1981
  ident: 844_CR33
  publication-title: J. Comput. Assist. Tomogr.
  doi: 10.1097/00004728-198102000-00027
– volume: 63
  start-page: 349
  year: 2008
  ident: 844_CR4
  publication-title: Biol. Psychiatry
  doi: 10.1016/j.biopsych.2007.05.028
– volume: 8
  start-page: 1122
  year: 2017
  ident: 844_CR5
  publication-title: ACS Chem. Neurosci.
  doi: 10.1021/acschemneuro.7b00074
– volume: 59
  start-page: 22
  issue: Suppl 20
  year: 1998
  ident: 844_CR27
  publication-title: J. Clin. Psychiatry
– volume: 31
  start-page: 1841
  year: 2006
  ident: 844_CR32
  publication-title: Neuropsychopharmacology
  doi: 10.1038/sj.npp.1301131
– volume: 102
  start-page: 75
  year: 2019
  ident: 844_CR42
  publication-title: Neuron
  doi: 10.1016/j.neuron.2019.03.013
– volume: 32
  start-page: 685
  year: 2012
  ident: 844_CR44
  publication-title: J. Cereb. Blood Flow. Metab.
  doi: 10.1038/jcbfm.2011.172
– volume: 23
  start-page: 59
  year: 2018
  ident: 844_CR22
  publication-title: Mol. Psychiatry
  doi: 10.1038/mp.2017.190
– volume: 580
  start-page: 239
  year: 2020
  ident: 844_CR21
  publication-title: Nature
  doi: 10.1038/s41586-020-2158-3
– volume: 309
  start-page: 200
  year: 2015
  ident: 844_CR40
  publication-title: Neuroscience
  doi: 10.1016/j.neuroscience.2015.04.047
– volume: 915
  start-page: 47
  year: 2001
  ident: 844_CR19
  publication-title: Brain Res.
  doi: 10.1016/S0006-8993(01)02823-2
– volume: 64
  start-page: 203
  year: 2001
  ident: 844_CR25
  publication-title: J. Affect Disord.
  doi: 10.1016/S0165-0327(00)00242-1
– volume: 54
  start-page: 573
  year: 2003
  ident: 844_CR31
  publication-title: Biol. Psychiatry
  doi: 10.1016/S0006-3223(02)01866-8
– volume: 9
  start-page: 467
  year: 2007
  ident: 844_CR2
  publication-title: Curr. Psychiatry Rep.
  doi: 10.1007/s11920-007-0063-1
– volume: 4
  year: 2014
  ident: 844_CR17
  publication-title: Transl. Psychiatry
  doi: 10.1038/tp.2013.112
– volume: 62
  start-page: 782
  year: 2012
  ident: 844_CR36
  publication-title: Neuroimage
  doi: 10.1016/j.neuroimage.2011.09.015
– volume: 235
  start-page: 1317
  year: 2018
  ident: 844_CR12
  publication-title: Psychopharmacology (Berl.)
  doi: 10.1007/s00213-018-4872-1
– volume: 36
  start-page: 1639
  year: 2009
  ident: 844_CR34
  publication-title: Eur. J. Nucl. Med. Mol. Imaging
  doi: 10.1007/s00259-009-1156-3
– volume: 31
  start-page: 113
  year: 2011
  ident: 844_CR24
  publication-title: J. Cereb. Blood Flow. Metab.
  doi: 10.1038/jcbfm.2010.55
– volume: 10
  start-page: 3318
  year: 2019
  ident: 844_CR10
  publication-title: ACS Chem. Neurosci.
  doi: 10.1021/acschemneuro.9b00288
– volume: 113
  start-page: 296
  year: 2007
  ident: 844_CR20
  publication-title: Pharm. Ther.
  doi: 10.1016/j.pharmthera.2006.08.004
– volume: 47
  start-page: 351
  year: 2000
  ident: 844_CR1
  publication-title: Biol. Psychiatry
  doi: 10.1016/S0006-3223(99)00230-9
– volume: 60
  start-page: 279
  year: 2009
  ident: 844_CR3
  publication-title: Brain Res. Rev.
  doi: 10.1016/j.brainresrev.2008.07.006
– volume: 174
  start-page: 42
  year: 2018
  ident: 844_CR18
  publication-title: Pharm. Biochem. Behav.
  doi: 10.1016/j.pbb.2017.12.010
– volume: 21
  start-page: 1298
  year: 2016
  ident: 844_CR43
  publication-title: Mol. Psychiatry
  doi: 10.1038/mp.2015.176
– volume: 41
  start-page: 301
  year: 2014
  ident: 844_CR48
  publication-title: Eur. J. Nucl. Med. Mol. Imaging
  doi: 10.1007/s00259-013-2529-1
– volume: 16
  start-page: 199
  year: 1990
  ident: 844_CR29
  publication-title: Health Policy
  doi: 10.1016/0168-8510(90)90421-9
– volume-title: ECDEU Assessment Manual for Psychopharmacology
  year: 1976
  ident: 844_CR28
– volume: 213
  start-page: 547
  year: 2011
  ident: 844_CR15
  publication-title: Psychopharmacology (Berl.)
  doi: 10.1007/s00213-010-1881-0
– volume: 68
  start-page: 892
  year: 2011
  ident: 844_CR14
  publication-title: Arch. Gen. Psychiatry
  doi: 10.1001/archgenpsychiatry.2011.91
– volume: 169
  start-page: 152
  year: 2012
  ident: 844_CR46
  publication-title: Am. J. Psychiatry
  doi: 10.1176/appi.ajp.2011.11010137
– volume: 68
  start-page: 480
  year: 2014
  ident: 844_CR45
  publication-title: Synapse
  doi: 10.1002/syn.21761
– volume: 134
  start-page: 382
  year: 1979
  ident: 844_CR30
  publication-title: Br. J. Psychiatry
  doi: 10.1192/bjp.134.4.382
– volume: 15
  start-page: 1167
  year: 2012
  ident: 844_CR6
  publication-title: Int. J. Neuropsychopharmacol.
  doi: 10.1017/S1461145711001945
– volume: 71
  start-page: 27
  year: 2016
  ident: 844_CR8
  publication-title: Prog. Neuropsychopharmacol. Biol. Psychiatry
  doi: 10.1016/j.pnpbp.2016.05.007
– volume: 16
  start-page: 606
  year: 2001
  ident: 844_CR26
  publication-title: J. Gen. Intern. Med.
  doi: 10.1046/j.1525-1497.2001.016009606.x
– volume: 9
  start-page: 471
  year: 1997
  ident: 844_CR41
  publication-title: J. Neuropsychiatry Clin. Neurosci.
  doi: 10.1176/jnp.9.3.471
– volume: 8
  start-page: 978
  year: 2017
  ident: 844_CR11
  publication-title: Front. Pharm.
  doi: 10.3389/fphar.2017.00978
– ident: 844_CR35
– volume: 7
  start-page: 308
  year: 1965
  ident: 844_CR39
  publication-title: Comput. J.
  doi: 10.1093/comjnl/7.4.308
SSID ssj0000548171
Score 2.4452024
Snippet The glutamate N -methyl- d -aspartate receptor antagonist ketamine has a rapid antidepressant effect. Despite large research efforts, ketamine’s mechanism of...
The glutamate N-methyl-d-aspartate receptor antagonist ketamine has a rapid antidepressant effect. Despite large research efforts, ketamine’s mechanism of...
The glutamate N-methyl-D-aspartate receptor antagonist ketamine has a rapid antidepressant effect. Despite large research efforts, ketamine's mechanism of...
SourceID pubmedcentral
proquest
crossref
springer
SourceType Open Access Repository
Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 159
SubjectTerms 59/78
631/154/436/2388
692/53/2423
692/699/476/1414
Antidepressants
Behavioral Sciences
Biological Psychology
Ketamine
Medicine
Medicine & Public Health
Neurosciences
Pharmacotherapy
Psychiatry
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NbtQwELagSIgLKn9ioSAjcQJZTWJ7bU5VQa0KEgjRVtpb5L-IFa2zkPTCI_A8PEGfrDOOk9VWaq_rJJt4xuNvfvwNIW8duMaw73AmpQtMCFcyI61jQZZNYUKBfWqw2uLb_OhUfFnIRQ64dbmscrSJyVD71mGMfBepuACtFPrD3uo3w65RmF3NLTTukntIXYZarRZqirEAHNGlKsdkJte7HdhsPFNWJUJTwcTmdrTGmNcrJK-lSdPuc7hNHmbYSPcHOT8id0J8TO5_zYnxJ-TfPoVNx7fny7_B01RoZVuW69DP4KfvByc0UcnStqG_Qm_O4b7L_x0dCjpoGykoY9tjdLb8SMEOhhW449Qu07EXuow0U7B2FGO39Pj4x2cGvjriz9jTqaI2PiWnhwcnn45YbrPAnFCyZ_MiSC-Nk9yA_xeC9VwAbCuM8jx4br3X3hpemaL088oBpGgER1PhuLIVQLhnZCu2MTwn1MJ8Nwom3msj8FRug0_2yDPmXeHKGSnG2a5d5iDHVhhndcqFc10PAqpBQDUKqBYz8m66ZTUQcNx28c4owjqvxa5ea84Nw1pVUus5vN2baRgWGWZOTAztxfAI2BngohlRG5oxvRPSdG-OxOXPRNetwEkFHDAj70cdWv_5jV_y4vYveUkeVEmJMRy0Q7b6PxfhFaCj3r5OS-AKi5QP9w
  priority: 102
  providerName: ProQuest
Title A randomized placebo-controlled PET study of ketamine´s effect on serotonin1B receptor binding in patients with SSRI-resistant depression
URI https://link.springer.com/article/10.1038/s41398-020-0844-4
https://www.proquest.com/docview/2408139089
https://www.proquest.com/docview/2487258861
https://www.proquest.com/docview/2408538886
https://pubmed.ncbi.nlm.nih.gov/PMC7261801
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3LatwwFL3kAaWb0PRBJ00GFbpqEbUtyVKXk2FCOtAQMgnMzuhlOjSxQ8fZ9BP6Pf2Cflmv5EeYlBS6MkhXtixd6T51BPDOommMcodRIaynnNuUamEs9SItE-2TcE9NyLY4y0-v-HwplluQ9mdhYtJ-hLSM23SfHfZxjZttOAyWRSRSTvk27AakdmTt3clkvpgPjhXUQVQq0z6CydTfbTdl0L1i-TAt8kFsNIqck2ew1-mKZNL2bh-2fPUcnnzpouEv4OeEoKRx9c3qh3ckZleZmnbJ59dYdD67JBE_ltQl-eYbfYPtfv9akzaLg9QVQQ6sm-CSTY8Jbn7-Fm1wYlbxrAtZVaTDXV2T4LAli8XFZ4oGelA6q4YMabTVS7g6mV1OT2l3twK1XIqG5okXTmgrmEajz3vjGEddLdHSMe-YcU45o1mmk9TlmUU9ouQs7A-WSZOh3vYKdqq68q-BGBzvUuLAO6V5OIpbhje7AC7mbGLTEST9aBe2Ax4P919cFzEAzlTRTlCBE1SECSr4CN4PTW5b1I1_ER_2U1h0C3BdBOQ2pEvUp0eqlcyEUjn27u1QjSsrhEt05eu79hUoDpBoBHKDM4Y-BWzuzZpq9TVidEu0TFH4j-BDz0P3H3_0Tw7-i_oNPM0iTweX0CHsNN_v_BFqSI0Zw7ZcynG3MvB5PDs7v8DSaT4dR6_DH3akEv0
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkYAL4im2FDASXEBWk9hehwNCBVrt0ocQ3Up7M47tiFXbZGlSIfgJ_BhO_AJ-GTPOY7WV2luvceIknhnPNw_PEPLCgmkMeoczKa1nQtiYGZlZ5mWcR8ZH2KcGsy32h6ND8WkqpyvkT3cWBtMquz0xbNSutOgj38BSXIBWovTNu_l3hl2jMLratdBo2GLH__wBJlv1dvwR6PsySba3Jh9GrO0qwKxQsmbDyEsnjZXcgLnjfea4AJQSGeW4dzxzLnWZ4YmJYjdMLGjQXHCUDMtVlgBigXmvkeugeCM09tRU9T4dgD9prOIueMrTjQp0BJ5hS0IBVcHEsvpbYNrzGZnnwrJB223fIbdbmEo3G766S1Z8cY_c2GsD8ffJ700KSs6VJ7Nf3tGQ2JWVrM17P4ZLn7cmNJSupWVOj3xtTuC5f38r2iSQ0LKgwPxljd7g-D2FfdfPwfyn2Swcs6GzgrYlXyuKvmJ6cPBlzE59hXi3qGmfwVs8IIdXQoCHZLUoC_-I0AzWO1ew8C41Ak8B5zizw7pmzkY2HpCoW21t25rn2HrjWIfYO091QyANBNJIIC0G5FX_yLwp-HHZzesdCXUr-5VecOoFw6lKZJoO4eue98Mg1BipMYUvz5opQBPBTQOiljij_yYsC748Usy-hfLgCoxiwB0D8rrjocXLL_yTtcv_5Bm5OZrs7erd8f7OY3IrCQyNrqh1slqfnvkngMzq7GkQB0q-XrX8_QdXgUyk
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VVKq4oPISgQKLBBfQKrZ3NzYHhFqaqKEQRX1IvZn17lqNaO00doXgJ_B7OHHklzHjR6JUam-9eu21vTOz881jZwBeGzSNUe8IrpRxXErjc60Sw53yU087j_rUULbFuL93LD-fqJM1-NuehaG0ynZPrDZqmxvykfeoFBeiFS9630ubtIjJ7vDj7IJTBymKtLbtNGoW2Xc_f6D5VnwY7SKt3wTBcHD0aY83HQa4kaEqed9zyiptlNBo-jiXWCERsXg6tMJZkVgb2USLQHu-7QcGtWkqBUmJEWESIHrBee_AekhWUQfWdwbjycHCw4NgKPJDvw2liqhXoMagE21BVU5VcrmqDJcI92p-5pUgbaX7hptwrwGtbLvmsvuw5rIHsPG1Ccs_hN_bDFWezc-nv5xlVZpXkvMmC_4ML00GR6wqZMvylH13pT7H5_79KVidTsLyjKEo5CX5hv0dhruwm5X5nCXT6tANm2asKQBbMPIcs8PDgxGfu4LQb1ayRT5v9giOb4UEj6GT5Zl7AizB9U5DXHgbaUlnglOa2VKVM2s843fBa1c7Nk0FdGrEcRZXkXgRxTWBYiRQTASKZRfeLh6Z1eU_brp5qyVh3OwERbzk22uGozBQUdTHr3u1GEYRp7iNzlx-WU-Beglv6kK4whmLb6Ii4asj2fS0KhYeoomMKKQL71oeWr782j95evOfvIQNlL34y2i8_wzuBhU_k19qCzrl_NI9R5hWJi8aeWDw7bZF8D9jolI_
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+randomized+placebo-controlled+PET+study+of+ketamine%C2%B4s+effect+on+serotonin1B+receptor+binding+in+patients+with+SSRI-resistant+depression&rft.jtitle=Translational+psychiatry&rft.au=Tiger%2C+Mikael&rft.au=Veldman%2C+Emma+R.&rft.au=Ekman%2C+Carl-Johan&rft.au=Halldin%2C+Christer&rft.date=2020-06-01&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2158-3188&rft.volume=10&rft.issue=1&rft_id=info:doi/10.1038%2Fs41398-020-0844-4&rft.externalDocID=10_1038_s41398_020_0844_4
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2158-3188&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2158-3188&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2158-3188&client=summon